Setmelanotide for the treatment of acquired hypothalamic obesity: a phase 2, open-label, multicentre trial
These findings support setmelanotide as a novel effective treatment of hypothalamic obesity.
These findings support setmelanotide as a novel effective treatment of hypothalamic obesity.
Join us for a special Ask Dr. Bob episode all about type 1 diabetes. Learn about who is at risk for type 1 diabetes and…
There are companies that are claiming to offer registration services for ADA’s Scientific Sessions, which are not affiliated with ADA and do not offer any…
Unlock the Power to Transform Lives: Discover the keys to clinically meaningful weight loss thresholds and revolutionize your approach to tackling obesity complications! In our…
Androgens can modulate immune cell function and may contribute to differences in the prevalence and severity of common inflammatory conditions. Although most immune cells are…
The findings in our study provide further evidence to strengthen the assertion of the non-inferiority of tenecteplase to alteplase, specifically when perfusion imaging has been…
ObesityWeek regular call for abstracts is open in March and April each year. The Late-Breaking Call for Abstracts is open in June and July each…
With thanks to the national societies who provided translations for these materials. The development and distribution of ESE hypoparathyroidism emergency cards is kindly supported by…
BOSTON — Explainable AI and systems that help providers with day-to-day tasks will allow experts to conduct more advanced research and make impactful changes in…
Phaeochromocytomas and paragangliomas (PPGLs) release catecholamines leading to catecholamine-induced hypertensive (CIH) crises, with blood pressure greater than or equal to 180/120 mm Hg. CIH crises…
Featured studies explored heart disease risk among people who have lived with obesity for a decade as well as predictors of weight gain among breast…